PP
CNCE

Paloma Partners’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Paloma Partners’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-28,512
Closed -$288K – 1368
2014
Q2 		$288K Buy
+28,512
New +$275K 0.01% 812

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Paloma Partners's CNCE Position: Q3 2014 in Review

Paloma Partners sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2014, closing a stake of 28,512 shares — an estimated $288K sold.

Paloma Partners first reported a position in CNCE in Q2 2014 and held it in 1 quarter. The position peaked at $288K in Q2 2014. 51 funds tracked by Wall St. Rank hold CNCE as of Q3 2014.

  • Paloma Partners reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Paloma Partners sold 28,512 Concert Pharmaceuticals, Inc. shares in Q3 2014, an estimated $288K.
  • Paloma Partners first reported a position in Concert Pharmaceuticals, Inc. in Q2 2014 and held it in 1 quarter.
  • Paloma Partners's Concert Pharmaceuticals, Inc. position peaked at $288K in Q2 2014.
  • 51 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2014.

Based on Paloma Partners's 13F filing for Q3 2014, filed 14 Nov 2014.